|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (defined as urinary albumin excretion greater than 300 mg/24 hr) was found in 7 out of 21 siblings to patients with nephropathy and 3 out of 30 siblings to normoalbuminuric patients (P less than 0.04).
|
1513092 |
1992 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
In one set, the probands (n = 11) had no evidence of diabetic nephropathy, with normal creatinine clearance and a urinary albumin excretion rate below 45 mg per day.
|
2710189 |
1989 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The observation suggests that changes in transglomerular albumin traffic are demonstrable prior to the onset of diabetes and diabetic nephropathy in subjects with a potential genetic predisposition to these conditions.
|
9150479 |
1997 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
In our case-control study, we assessed the prevalence of hypertension among parents of 73 IDDM patients with diabetic nephropathy (DN+; persistent albuminuria > 200 microg/min or > 300 mg/24 h) and 73 IDDM patients without diabetic nephropathy (DN-; urinary albumin excretion < 20 microg/min or < 30 mg/24 h).
|
9519751 |
1998 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, in a large ethnically homogeneous cohort of diabetic subjects, our data show: (1) a significant association of C708/T polymorphism with microalbuminuria in long-term diabetes and with both lower plasma ANP levels and widespread albumin leakage; and (2) a strong association between ScaI polymorphism and both diabetic nephropathy and plasma ANP concentrations.
|
10405209 |
1999 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Grade of diabetic nephropathy was determined using the amount of urinary excretion of albumin.
|
11576951 |
2001 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genomic DNA was obtained from 659 patients: 307 with normal urinary albumin excretion despite diabetes duration of >15 years (control subjects) and 352 with advanced diabetic nephropathy, of whom 200 had persistent proteinuria and 152 had end-stage renal disease (ESRD).
|
11916943 |
2002 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Since advanced glycation end products (AGEs; AGE-albumin) and in particular carboxymethyllysine (CML) are known to play a central role in diabetic nephropathy, we studied the activation of nuclear factor kappaB (NF-kappaB) in tubular epithelial cells in vivo and in vitro by AGE-albumin and CML.
|
12453911 |
2002 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.
|
12606536 |
2003 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.
|
12663475 |
2003 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To test this hypothesis we searched for association between the A-->G (-3862) variant in UCP1, the insertion/deletion (I/D) polymorphism in exon 8 in UCP2, and the C-->T (-55) polymorphism in UCP3 and diabetic nephropathy in 218 diabetic patients with normal urinary albumin excretion rate (AER), 216 with micro- or macroalbuminuria, and in 106 control subjects without a family history of diabetes.
|
15120704 |
2004 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The urinary excretion of VEGF and sFLT-1 increased at a relatively early stage in diabetic nephropathy associated with urinary albumin excretion.
|
15610240 |
2005 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Measurements LMNA 1908C/T polymorphism (by polymerase chain reaction restriction fragment length polymorphism, PCR-RFLP); diabetic retinopathy (by standard fundus photography); diabetic nephropathy (by urinary albumin excretion rate); diabetic neuropathy (by signs, symptoms and/or nerve conduction velocity); coronary heart disease (by symptoms of typical chest pain and/or history of myocardial infarction, and ischaemic electrocardiographic alteration and/or coronary artery bypass graft surgery); cerebral vascular disease (by ultrasonography, computed tomography and/or magnetic resonance imaging).
|
16117820 |
2005 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The main hallmark of diabetic nephropathy is elevation in urinary albumin excretion.
|
16374433 |
2006 |
|
Diabetic Nephropathy
|
0.600 |
Therapeutic
|
disease |
CTD_human |
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
|
16380483 |
2006 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Incipient DN was defined as an albumin excretion rate (AER) of 20-200 microg/min (n = 336).
|
17101543 |
2006 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy was defined as macroalbuminuria (urinary albumin excretion rate >200 microg/min or >300 mg/24 h) or end-stage renal disease.
|
17337502 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
An albumin excretion rate (AER) of 20-200 microg/min (n=73) was considered as incipient DN, and an AER >200 microg/min was considered as overt DN (n=48).
|
18413189 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A total of 458 cases with diabetic nephropathy (albumin excretion >300 mg/24h) and 319 controls with persistent normoalbuminuria (<30 mg/24h), despite > or =20 years of diabetes duration at follow-up were identified.
|
19246226 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, ESAM may regulate albumin extravasation at the glomeruli and play a role in the initiation of diabetic nephropathy.
|
19323980 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
RGD |
The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
|
19397971 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
RGD |
Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL.
|
19424163 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A total of 441 cases with diabetic nephropathy (albumin excretion > or =300 mg/24 h) and 314 controls with persistent normoalbuminuria (<30 mg/24 h), despite diabetes of duration > or =20 years, were identified.
|
19834686 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thirdly, reno-protective effects of PPARγ ligands, especially on reducing urinary albumin, have been observed in both animals and human not only in diabetic nephropathy but also in non-diabetic renal diseases.
|
20890053 |
2010 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The patients whose DN progressed had significantly higher urine albumin/creatinine ratios and fewer used diuretics than those in whom DN did not progress.
|
21346330 |
2011 |